Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.

A man standing near Donald Trump in the Oval Office collapsed as the president was holding a press event to announce discounts to two popular weight loss drugs.

Consumers are set to pay between $245 and $350 per month for obesity drugs including Wegovy and Zepbound.